MAIA Biotechnology Activates Clinical Trial Site in Georgia
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 18 2026
0mins
Source: Newsfilter
- Trial Expansion: MAIA Biotechnology has activated its THIO-101 expansion trial at the Winship Cancer Institute in Georgia, now enrolling patients to evaluate the efficacy of its lead immunotherapy agent, ateganosine, for non-small cell lung cancer, marking a significant advancement in its clinical stage.
- Addressing Treatment Gaps: Lung cancer is the leading cause of cancer-related deaths in Georgia, with over 7,300 new cases expected in 2025; if approved, MAIA's ateganosine could fill a critical void in treatment options for advanced non-small cell lung cancer patients lacking FDA-approved therapies, highlighting its clinical importance.
- Promising Early Efficacy: Initial results from the THIO-101 trial indicate that some patients have exceeded two years of survival, suggesting that the combination of ateganosine and PD-(L)1 inhibitors may lead to durable tumor regression in patients resistant to existing therapies, showcasing a strong clinical outlook.
- Strong Research Team: The Winship Cancer Institute boasts a premier thoracic oncology clinical research team, with principal investigator Dr. Ticiana Leal having extensive experience in lung cancer chemotherapy and immunotherapy, ensuring high quality and effectiveness of the trial.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MAIA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MAIA
Wall Street analysts forecast MAIA stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.470
Low
14.00
Averages
14.00
High
14.00
Current: 1.470
Low
14.00
Averages
14.00
High
14.00
No data
About MAIA
MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. The Company's THIO (6-thio-dG, 6-thio-2'-deoxyguanosine), is a lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The modified nucleotide 6-thio-2-deoxyguanosine (THIO) induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. THIO-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment with THIO followed by PD-(L)1 inhibitors resulted in tumor regression in advanced, in vivo cancer models by induction of cancer type-specific immune memory. THIO is being developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
MAIA Biotechnology Reports Positive Efficacy Data for Cancer Drug
- Clinical Trial Progress: MAIA Biotechnology's Part C results from the Phase 2 THIO-101 trial for non-small cell lung cancer show a disease control rate of 90.5%, significantly higher than the 25%-35% seen with existing chemotherapy, indicating the drug's substantial potential in treating resistant tumors.
- Innovative Treatment Regimen: The study evaluates Ateganosine as a third-line treatment for patients who have previously undergone checkpoint inhibitor and chemotherapy, utilizing a 21-day cycle of Ateganosine followed by cemiplimab, aimed at improving patient survival and quality of life.
- Accelerated Approval Plans: MAIA intends to seek accelerated approval from the FDA for Ateganosine, reflecting the company's confidence in the drug and its urgency to bring it to market to address unmet medical needs.
- Global Trial Expansion: The company has initiated a Phase 3 trial enrolling up to 300 patients in Taiwan, Turkey, EMA member states, and Georgia, demonstrating MAIA's commitment to advancing its clinical research on a global scale.
See More
MAIA Biotechnology Reports Positive Initial Efficacy Data from THIO-101 Clinical Trial
- Significant Disease Control Rate: The THIO-101 Part C clinical trial shows a 90.5% disease control rate (19 out of 21 patients), significantly exceeding the 25-35% control rate of current chemotherapy, indicating the drug's potential in heavily pre-treated patients.
- Efficacy Consistency: Initial data aligns with previous results from Parts A and B, achieving an 88% disease control rate in third-line NSCLC patients, suggesting stable efficacy across different patient populations and potential new treatment options.
- Acceptable Safety Profile: The combination of ateganosine and cemiplimab has demonstrated an acceptable safety profile in heavily pre-treated patients, enhancing the company's confidence in cancer immunotherapy and potentially driving further clinical development.
- Completion of International Enrollment: MAIA has completed international enrollment for Part C of THIO-101, marking an expansion of the company's clinical trial capabilities globally, which is expected to accelerate the drug's market entry and enhance competitive positioning.
See More
MAIA Biotechnology Completes International Enrollment for THIO-101 Trial
- Trial Progress: MAIA Biotechnology announced the completion of international enrollment for Part C of the THIO-101 expansion trial, aimed at assessing Ateganosine's efficacy in treating advanced non-small cell lung cancer, marking a significant milestone in the company's clinical trials.
- Drug Mechanism: Ateganosine acts as an investigational telomere-targeting agent that modifies telomeres through nucleotide substitution, ultimately causing DNA damage and selective cancer cell death, showcasing its potential in cancer treatment.
- Survival Data: In Parts A and B of the THIO-101 trial, the median survival was found to be 17.8 months, with eight patients achieving overall survival beyond two years, and one patient surviving over 33 months, indicating the drug's effectiveness.
- International Enrollment Completion: The trial successfully enrolled 41 patients across Taiwan, Turkey, Poland, Hungary, Romania, and Georgia, while screening is still ongoing in the U.S., demonstrating MAIA's capability in conducting clinical research on a global scale.
See More
MAIA Biotechnology Activates Clinical Trial Site in Georgia
- Trial Expansion: MAIA Biotechnology has activated its THIO-101 expansion trial at the Winship Cancer Institute in Georgia, now enrolling patients to evaluate the efficacy of its lead immunotherapy agent, ateganosine, for non-small cell lung cancer, marking a significant advancement in its clinical stage.
- Addressing Treatment Gaps: Lung cancer is the leading cause of cancer-related deaths in Georgia, with over 7,300 new cases expected in 2025; if approved, MAIA's ateganosine could fill a critical void in treatment options for advanced non-small cell lung cancer patients lacking FDA-approved therapies, highlighting its clinical importance.
- Promising Early Efficacy: Initial results from the THIO-101 trial indicate that some patients have exceeded two years of survival, suggesting that the combination of ateganosine and PD-(L)1 inhibitors may lead to durable tumor regression in patients resistant to existing therapies, showcasing a strong clinical outlook.
- Strong Research Team: The Winship Cancer Institute boasts a premier thoracic oncology clinical research team, with principal investigator Dr. Ticiana Leal having extensive experience in lung cancer chemotherapy and immunotherapy, ensuring high quality and effectiveness of the trial.
See More
MAIA Biotechnology Expands Phase 2 Trial for Ateganosine
- Trial Expansion: MAIA Biotechnology has announced the expansion of its Phase 2 THIO-101 trial for Ateganosine to a second clinical testing site in the U.S., aiming to treat non-small cell lung cancer and further validate the drug's clinical potential.
- Innovative Drug Mechanism: As the first-in-class telomere-targeting agent, Ateganosine attacks cancer cell telomeres, triggering immune responses that lead to tumor regression, showcasing its application prospects in patients who have failed chemotherapy.
- Global Trial Network: The trial is currently ongoing across 44 global sites, including two in the U.S., with MAIA planning to enroll up to 300 patients at these sites to support its goal of seeking accelerated FDA approval.
- Market Performance: MAIA's stock is currently trading at $1.34, up 3.47%, reflecting positive market sentiment regarding its clinical progress, which may pave the way for future financing and partnership opportunities.
See More
MAIA Biotechnology Advances THIO-101 Expansion Trial with New Clinical Site
- Clinical Trial Expansion: MAIA Biotechnology has activated its second U.S. clinical site for the THIO-101 expansion trial, now ongoing at 44 active sites across the U.S. and Europe, demonstrating the company's strong execution in the non-small cell lung cancer treatment space.
- Significant Market Potential: The potential breakthrough therapy of THIO-101 holds a substantial position in the projected $70 billion global non-small cell lung cancer market, indicating MAIA's strategic significance in the cancer immunotherapy landscape.
- Enhanced Patient Recruitment Efficiency: By broadening its clinical trial site footprint, MAIA can recruit patients more efficiently, advancing the program under FDA Fast Track designation and moving towards upcoming interim data milestones.
- Global Regulatory Approvals: MAIA has received regulatory approval to screen patients in Taiwan, Turkey, and select European countries, further expanding its clinical trial's international reach and enhancing its competitive edge in the global market.
See More
MAIA Biotechnology Reports Positive Efficacy Data for Cancer Drug
- Clinical Trial Progress: MAIA Biotechnology's Part C results from the Phase 2 THIO-101 trial for non-small cell lung cancer show a disease control rate of 90.5%, significantly higher than the 25%-35% seen with existing chemotherapy, indicating the drug's substantial potential in treating resistant tumors.
- Innovative Treatment Regimen: The study evaluates Ateganosine as a third-line treatment for patients who have previously undergone checkpoint inhibitor and chemotherapy, utilizing a 21-day cycle of Ateganosine followed by cemiplimab, aimed at improving patient survival and quality of life.
- Accelerated Approval Plans: MAIA intends to seek accelerated approval from the FDA for Ateganosine, reflecting the company's confidence in the drug and its urgency to bring it to market to address unmet medical needs.
- Global Trial Expansion: The company has initiated a Phase 3 trial enrolling up to 300 patients in Taiwan, Turkey, EMA member states, and Georgia, demonstrating MAIA's commitment to advancing its clinical research on a global scale.
See More
MAIA Biotechnology Reports Positive Initial Efficacy Data from THIO-101 Clinical Trial
- Significant Disease Control Rate: The THIO-101 Part C clinical trial shows a 90.5% disease control rate (19 out of 21 patients), significantly exceeding the 25-35% control rate of current chemotherapy, indicating the drug's potential in heavily pre-treated patients.
- Efficacy Consistency: Initial data aligns with previous results from Parts A and B, achieving an 88% disease control rate in third-line NSCLC patients, suggesting stable efficacy across different patient populations and potential new treatment options.
- Acceptable Safety Profile: The combination of ateganosine and cemiplimab has demonstrated an acceptable safety profile in heavily pre-treated patients, enhancing the company's confidence in cancer immunotherapy and potentially driving further clinical development.
- Completion of International Enrollment: MAIA has completed international enrollment for Part C of THIO-101, marking an expansion of the company's clinical trial capabilities globally, which is expected to accelerate the drug's market entry and enhance competitive positioning.
See More
MAIA Biotechnology Completes International Enrollment for THIO-101 Trial
- Trial Progress: MAIA Biotechnology announced the completion of international enrollment for Part C of the THIO-101 expansion trial, aimed at assessing Ateganosine's efficacy in treating advanced non-small cell lung cancer, marking a significant milestone in the company's clinical trials.
- Drug Mechanism: Ateganosine acts as an investigational telomere-targeting agent that modifies telomeres through nucleotide substitution, ultimately causing DNA damage and selective cancer cell death, showcasing its potential in cancer treatment.
- Survival Data: In Parts A and B of the THIO-101 trial, the median survival was found to be 17.8 months, with eight patients achieving overall survival beyond two years, and one patient surviving over 33 months, indicating the drug's effectiveness.
- International Enrollment Completion: The trial successfully enrolled 41 patients across Taiwan, Turkey, Poland, Hungary, Romania, and Georgia, while screening is still ongoing in the U.S., demonstrating MAIA's capability in conducting clinical research on a global scale.
See More
MAIA Biotechnology Activates Clinical Trial Site in Georgia
- Trial Expansion: MAIA Biotechnology has activated its THIO-101 expansion trial at the Winship Cancer Institute in Georgia, now enrolling patients to evaluate the efficacy of its lead immunotherapy agent, ateganosine, for non-small cell lung cancer, marking a significant advancement in its clinical stage.
- Addressing Treatment Gaps: Lung cancer is the leading cause of cancer-related deaths in Georgia, with over 7,300 new cases expected in 2025; if approved, MAIA's ateganosine could fill a critical void in treatment options for advanced non-small cell lung cancer patients lacking FDA-approved therapies, highlighting its clinical importance.
- Promising Early Efficacy: Initial results from the THIO-101 trial indicate that some patients have exceeded two years of survival, suggesting that the combination of ateganosine and PD-(L)1 inhibitors may lead to durable tumor regression in patients resistant to existing therapies, showcasing a strong clinical outlook.
- Strong Research Team: The Winship Cancer Institute boasts a premier thoracic oncology clinical research team, with principal investigator Dr. Ticiana Leal having extensive experience in lung cancer chemotherapy and immunotherapy, ensuring high quality and effectiveness of the trial.
See More
MAIA Biotechnology Expands Phase 2 Trial for Ateganosine
- Trial Expansion: MAIA Biotechnology has announced the expansion of its Phase 2 THIO-101 trial for Ateganosine to a second clinical testing site in the U.S., aiming to treat non-small cell lung cancer and further validate the drug's clinical potential.
- Innovative Drug Mechanism: As the first-in-class telomere-targeting agent, Ateganosine attacks cancer cell telomeres, triggering immune responses that lead to tumor regression, showcasing its application prospects in patients who have failed chemotherapy.
- Global Trial Network: The trial is currently ongoing across 44 global sites, including two in the U.S., with MAIA planning to enroll up to 300 patients at these sites to support its goal of seeking accelerated FDA approval.
- Market Performance: MAIA's stock is currently trading at $1.34, up 3.47%, reflecting positive market sentiment regarding its clinical progress, which may pave the way for future financing and partnership opportunities.
See More
MAIA Biotechnology Advances THIO-101 Expansion Trial with New Clinical Site
- Clinical Trial Expansion: MAIA Biotechnology has activated its second U.S. clinical site for the THIO-101 expansion trial, now ongoing at 44 active sites across the U.S. and Europe, demonstrating the company's strong execution in the non-small cell lung cancer treatment space.
- Significant Market Potential: The potential breakthrough therapy of THIO-101 holds a substantial position in the projected $70 billion global non-small cell lung cancer market, indicating MAIA's strategic significance in the cancer immunotherapy landscape.
- Enhanced Patient Recruitment Efficiency: By broadening its clinical trial site footprint, MAIA can recruit patients more efficiently, advancing the program under FDA Fast Track designation and moving towards upcoming interim data milestones.
- Global Regulatory Approvals: MAIA has received regulatory approval to screen patients in Taiwan, Turkey, and select European countries, further expanding its clinical trial's international reach and enhancing its competitive edge in the global market.
See More
